Stay updated on Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The completed KEYNOTE-033 Phase 3 study record is now available, detailing pembrolizumab versus docetaxel for previously treated non-small cell lung cancer, along with its eligibility criteria, measures, investigators, publication, and study documents.
    Difference
    57%
    Check dated 2026-11-07T13:15:16.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0. The study record still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T13:57:29.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    A sitewide NIH notice announces that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during a transition. The clinical trial page itself continues to display a 403 error.
    Difference
    1%
    Check dated 2026-10-24T16:19:43.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The site revision label in the footer changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T16:09:58.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The footer’s site revision changed from v3.7.0 to v3.7.1; the page still displays a 403 error.
    Difference
    0.2%
    Check dated 2026-10-10T16:12:21.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    The study page now renders a 403 Forbidden error, signaling that the page is temporarily inaccessible. The usual study details and navigation are replaced by the error screen.
    Difference
    19%
    Check dated 2026-09-19T20:50:17.000Z thumbnail image

Stay in the know with updates to Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Docetaxel in NSCLC: Clinical Trial page.